Biocon Q4 Results
Biocon Q4 Results: On Thursday, May 16, Biocon revealed its January–March quarter results for fiscal 2023–24 (Q4FY24).
The company reported a 57% decrease in consolidated net profit at ₹135.5 crore, as opposed to ₹313.2 crore during the same period the previous year.
The pharmaceutical company's operating revenue for the fourth quarter of FY24 was ₹3,917 crore, up 4% from ₹3,774 crore in the same time the previous year.
One of the top biopharma companies in India is Biocon. Delivering biopharma solutions from discovery to development and commercialization, it is fully integrated.
Its revenue streams are diverse and include small compounds and APIs, contract research, and biosimilars (including branded formulations).
Please note that the content featured on the website spans a wide array of topics including business, finance, investing, education, jobs, and money matters. We curate this content from a variety of internet sources and occasionally change it with our research, adapting it to suit our editorial standards and presentation style. While we strive for accuracy and reliability, it's important to recognize that the information provided on our website is intended for general informational purposes only. We recommend readers independently verify key details or seek professional advice before making any decisions based on the content presented. Additionally, please be aware that our content may undergo modifications to enhance clarity, relevance, and originality. By accessing MATKA.CYOU, users acknowledge and consent to this approach to content presentation. Thank you for your understanding and continued support. Warm regards, MATKA Editorial Team
The matka is a website where you can find information about finance-related terms.